Vanguard Group’s Immunocore IMCR Stock Holding History

Vanguard Group’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,202	Closed	-$385K	–	4542
2022 Q3	$385K	Buy	+8,202	New	+$391K	﹤0.01%	4286

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group's IMCR Position: Q4 2022 in Review

Vanguard Group sold out of Immunocore (IMCR) in Q4 2022, closing a stake of 8,202 shares — an estimated $385K sold.

Vanguard Group first reported a position in IMCR in Q3 2022 and held it in 1 quarter. The position peaked at $385K in Q3 2022. 104 funds tracked by Wall St. Rank hold IMCR as of Q4 2022.

Vanguard Group reported no remaining Immunocore position as of Q4 2022 after selling out during the quarter.
Vanguard Group sold 8,202 Immunocore shares in Q4 2022, an estimated $385K.
Vanguard Group first reported a position in Immunocore in Q3 2022 and held it in 1 quarter.
Vanguard Group's Immunocore position peaked at $385K in Q3 2022.
104 funds tracked by Wall St. Rank held Immunocore as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.